|Podcasts|July 16, 2013
What does RBM mean to Sanofi's CRAs and site monitors
Lori Convy, Assistant Director, Clinical Research Monitoring, Sanofi discusses what risk-based monitoring mean to Sanofi's CRAs and site monitors?
Advertisement
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Beyond Compliance: YPrime's Paulo Limgenco on Moving ESG From Reporting to Real Business Value
2
FDA Finalizes Three Guidances to Broaden Cancer Clinical Trial Eligibility
3
ACT Brief: Data Pipeline Standardization for Real-Time Analysis, Sponsor Accountability Beyond Contracts, and Autoimmune Pipeline Expansion
4
ACT Brief: Inspection Readiness Throughout Lifecycle, AI Churn and Operational Discipline, and Global Trial Stakeholder Alignment
5